Rivaroxaban vs. Low Molecular Weight Heparin for DVT Management
Study Overview
This study compares the effectiveness and safety of rivaroxaban and low molecular weight heparin (LMWH) for treating lower extremity deep vein thrombosis (DVT) after thoracoscopic lung cancer surgery.
Study Details
Sixty patients with DVT were randomly divided into two groups:
- Experimental Group: 30 patients received rivaroxaban.
- Control Group: 30 patients received LMWH.
Key patient information and ultrasound results were recorded before and after surgery. The patients were monitored for three months, with data collected at one and three months post-surgery.
Results
- Both groups showed good wound healing after surgery.
- D-dimer levels remained stable, indicating no new blood clots.
- No serious complications like pleural effusion or gastrointestinal bleeding were reported.
- Six patients in the control group had bruising at LMWH injection sites.
Conclusion
Rivaroxaban is as effective as LMWH for DVT treatment after lung cancer surgery and has a better safety profile.
Practical Solutions and Value
Clinical trials are essential for creating safe and effective treatments. To make these benefits available in everyday practice, we offer DocSym, an AI-driven platform that combines ICD-11 standards, clinical protocols, and research into one easy-to-use resource for healthcare providers.
In today’s healthcare landscape, efficiency is key. Our mobile apps help with scheduling, treatment monitoring, and telemedicine, simplifying patient care management and expanding digital services.
By leveraging AI, clinics can streamline their workflows, improve patient outcomes, and reduce paperwork. Discover how we can assist you at aidevmd.com.
